Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
4,801 results
  • Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus. [Journal Article]
  • ACAnn Clin Microbiol Antimicrob 2018 Feb 20; 17(1):5
  • Gern BH, Greninger AL, … Qin X
  • CONCLUSIONS: Cefazolin continues to be the recommended agent for MSSA treatment at our institution, reflected by the finding that only 2% (6/321) of patients who received ceftriaxone as definitive therapy for MSSA bacteremia during the study period. We have confirmed the cefoxitin-predicted MSSA susceptibility to cefazolin, but have found concerning drifts in ceftriaxone susceptibilities by continued in vitro monitoring over the last 6 years.
New Search Next